April 2023, AquaHeart was honored to be listed as a top 10 solution provider in the cardiovascular space. Our CEO, Dr. Holger Friedrich, highlighted the remarkable benefits of the AquaHeart system in an article, solidifying our position as leaders in the field of Pulmonary Vein Isolation. We are proud to be driving advancements that will reshape the landscape of cardiac care.
By the time a human reaches age 65 its heart will have beaten over two billion times. This enormous performance wears on the heart muscle. It is estimated that for up to 15% of humans this strain can result in Atrial Fibrillation, leading to a higher risk of stroke.
Current market studies estimate that roughly 1 million heart ablations are performed every year, comparing this to a global population of 700 million people above the age of 65.
So current technologies do not scale to the needed level.
As only 10% of the treatable population in need are treated, we made it our mission to develop a technology that can be applied faster, safer, and more easily, so that we can address the huge majority currently not served. The “over the wire” technique allows for fast and safe single shot Pulmonary Vein insulation.
The Aqua Group of companies have developed a technology platform consisting of multiple patent families and medical devices of which the first have passed FDA approval and are in First-In-Human (FIH) stage.
Aqua Heart works with global leading experts in the field of Heart Ablations as well as medical device engineers to build a globally applicable, safe and easy to use, single-shot-high-energy heart ablation system.
Aqua Heart was founded in 2018 based on already successful developments of other companies in the Aqua Group.
Aqua Heart´s medical device is in advanced stage of development and regulatory approval.
Atrial Fibrillation is a potentially deadly condition, yet only 10% of patients receive curative treatment today. At AquaHeart, we are on a mission to change that. Our groundbreaking high-energy, short-duration, single-shot Pulmonary Vein Isolation technology is paving the way for accessible treatment on a global scale.
By developing a solution that can be applied faster, safer, and more easily, we are addressing a large unmet need of untreated Atrial Fibrillation patients. With AquaHeart, heart ablation is no longer limited to a select few—it is now within reach for all patients and interventional cardiologist.
Heart Ablations today need the highest skilled electro-physiologist cardiologists with large supporting teams in their catheter laboratories.
Aqua Heart´s technology is developed in a way that complicated mapping procedures are not required, and the system provides real time success feedback.
Electro physiology catheter laboratories are only available in highly specialized clinics due to their cost and complexity.
Aqua Heart´s technology uses a strictly anatomical approach, which reduces several of the traditional preconditions to provide ablative Atrial Fibrillation therapy.
Our team of world leading cardio and medical engineering experts
Serial entrepreneur with 30+years experience in medical devices, esp. Cardiovascular,
ex St. Jude, ex Ventritex
Consulting CFO to >50 early-stage life sciences companies. MBA/CPA
President and CEO of Procyrion inc., Houston
Former Group President, St. Jude Medical/Abbott
Positions at AVE, Medtronic, Synecor, Innerpulse, Creganna Medical. Long term catheter development expertise
Sole director and Chief Executive Officer of Three Heads Investment S.r.l.: Former CEO and Director at Sofar S.p.A. (“Sofar”). President and board member of 1LAB SA. Sole director of BLL Invest srl. Member of the Board of Asensus Surgical, inc. (NYSE).
COO of Inspire inc. former CTO St. Jude/Abbott
Cardiologist in Minneapolis, Minnesota and is affiliated with Minneapolis Veterans Affairs Health Care System. He received his medical degree from Bangalore Medical College and has been in practice for more than 20 years.
Expert and scientific researcher in EP, especially ventricular ablation programs
Founder, Inventor, Serial Entrepreneur, Doctor of Gastroenterology, former Professor at Mayo Clinic
Dr. VK Sharma is a practicing gastroenterologist and a serial entrepreneur with 20+ years of experience. He held the positions of Professor of Medicine at the Mayo Clinic School of Medicine and Vice-Chair of Gastroenterology Research, making significant contributions to the field.
Dr. Sharma has founded multiple successful MedTech device startups in gastrointestinal endoscopy, surgery, cardiology, Women's Health, and Consumer Health. These ventures have secured over $100 million in venture funding, showcasing confidence in his innovative ideas.
With a strong focus on innovation, Dr. Sharma possesses an impressive portfolio of 100+ issued US and international patents. His contributions to medical science include 300+ peer-reviewed articles, book chapters, research abstracts, and presentations. He has been recognized by Stanford University, being listed among the world's top 2% of scientists.
Dr. Sharma's achievements have garnered him recognition and fellowship in esteemed organizations such as the American Gastroenterological Association, the American College of Gastroenterology, and the American Society for Gastrointestinal Endoscopy. Through his expertise and entrepreneurial drive, he continues to shape the future of gastroenterology and healthcare
2020 - present
Founder, Chairman, CEO, Libero Health Inc.
2019 - present
Founder, Director, AquaTherapeutic Inc.
2018 - present
Founder, Director, aGUaRx Inc.
2017 - present
Founder, Director, AquaHeart Inc.
2017 - present
Founder, Director, Chief Medical Officer, Attract Medical Inc.
2016 - present
Founder, Director, Chief Medical Officer, Aqua Medical Inc.: 2016
2009 - 2019
Founder, Director, Chief Medical Officer: EndoStim Inc.
2013 - 2016
Founder, Director, Chief Medical Officer: SynerZ Inc.
2010 - present
Founder, Gastroenterologist, Arizona Centers for Digestive Health
Address: 191 W. Second St., Santa Ana, CA 92701, USA